Stefan Schandelmaier
Overview
Explore the profile of Stefan Schandelmaier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1763
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goetz G, Schandelmaier S, Busse R, Wild C, Panteli D
Int J Technol Assess Health Care
. 2025 Feb;
41(1):e9.
PMID: 39909858
Objectives: The EUnetHTA Core Model is well-established in the HTA community. Some recommendations of corresponding guidance documents leave room for alternative methodological choices. Considering the new HTA regulation (HTAR), we...
2.
Griessbach A, Speich B, Amstutz A, Hausheer L, Covino M, Wnfried Ramirez H, et al.
J Clin Epidemiol
. 2024 Sep;
176:111536.
PMID: 39307405
Background And Objectives: Conducting high-quality randomized clinical trials (RCTs) is challenging and resource intensive. Funders and academic investigators depend on limited financial resources and, therefore, need empirical data for optimal...
3.
Amstutz A, Schonenberger C, Speich B, Griessbach A, Schwenke J, Glasstetter J, et al.
J Clin Epidemiol
. 2024 Jul;
174:111469.
PMID: 39032590
Objectives: Trials within Cohorts (TwiCs) is a pragmatic design approach that may overcome frequent challenges of traditional randomized trials such as slow recruitment, burdensome consent procedures, or limited external validity....
4.
Wang Y, Parpia S, Ge L, Heels-Ansdell D, Lai H, Esfahani M, et al.
NEJM Evid
. 2024 Jun;
3(7):EVIDoa2400134.
PMID: 38874580
Background: The goal of this systematic review was to examine the efficacy and safety of proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Methods: We included randomized trials...
5.
Schandelmaier S, Guyatt G
JAMA Netw Open
. 2024 Mar;
7(3):e243339.
PMID: 38546652
No abstract available.
6.
Griessbach A, Schonenberger C, Taji Heravi A, Gloy V, Agarwal A, Hallenberger T, et al.
JAMA Netw Open
. 2024 Mar;
7(3):e243109.
PMID: 38506807
Importance: Platform trials have become increasingly common, and evidence is needed to determine how this trial design is actually applied in current research practice. Objective: To determine the characteristics, progression,...
7.
Hirt J, Ewald H, Briel M, Schandelmaier S
J Clin Epidemiol
. 2023 Nov;
166:111201.
PMID: 37914105
No abstract available.
8.
Guyatt G, Zhao Y, Mayer M, Briel M, Mustafa R, Izcovich A, et al.
J Clin Epidemiol
. 2023 Mar;
158:70-83.
PMID: 36898507
Objectives: To update previous Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidance by addressing inconsistencies and interpreting subgroup analyses. Study Design And Setting: Using an iterative process, we consulted...
9.
Amstutz A, Speich B, Mentre F, Rueegg C, Belhadi D, Assoumou L, et al.
Lancet Respir Med
. 2023 Feb;
11(5):453-464.
PMID: 36828006
Background: Interpretation of the evidence from randomised controlled trials (RCTs) of remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the benefits and harms of...
10.
Hirt J, Schonenberger C, Ewald H, Lawson D, Papola D, Rohner R, et al.
JAMA Netw Open
. 2023 Feb;
6(2):e2253198.
PMID: 36787138
Importance: Improving methodological quality is a priority in the health research community. Finding appropriate methods guidance can be challenging due to heterogeneous terminology, poor indexing in medical databases, and variation...